CALR and neoplasm: Our data implies that the presence of HPV16 E7 (aa49-57) CTL epitope in wild type E7 -expressing tumor does not seem capable of completely suppressing the presentation of HPV16 E7(aa11-20) through HLA-A2 molecule in the tumor model as the tumor can be controlled by vaccination with CRT/E7(N53S) DNA vaccine.